Eli Lilly and Baseline Therapeutics Investigate GLP-1s for Substance Use Disorders
Lilly and startup Baseline Therapeutics are investigating GLP-1 RAs for alcohol and substance use disorders. A large VA study found GLP-1s associated with reduced substance abuse risk, in a therapeutic area projected to reach $12.4B by 2033.